GO
Loading...

$8.3 billion biotech deal

Monday, 25 Aug 2014 | 5:00 PM ET

Robyn Karnauskas, Deutsche Bank biotechnology analysis, discusses which companies could be the next takeover target in the biotech space following Roche's acquisition of InterMune.